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MACKGROUND & AIMS: Germline phosphatase and ten-
in homolog (PTEN) mutations cause Cowden syndrome
CS), associated with breast and thyroid cancers. Case
eports found 35%– 85% of CS patients had gastrointes-
inal (GI) hamartomas. The association of benign and
alignant GI neoplasias with CS remains debatable. Our
oal is to describe the GI phenotype in a prospective
eries of PTEN mutation carriers. METHODS: Patients
ho met relaxed International Cowden Consortium cri-
eria (N  2548) or with 5 or more GI polyps, 1 or more
f which was hyperplastic or hamartomatous (N  397),
ere prospectively recruited. Germline PTEN mutation/
eletion analysis was performed. Of the 2945 patients,
27 (123 of 2548 and 4 of 397, respectively) patients
aving clear pathogenic PTEN mutations were eligible for
his study. Esophagogastroduodenoscopy, colonoscopy,
nd pathology reports were reviewed. The Fisher 2-tailed
xact test, unpaired t tests, and age- and sex-adjusted
tandardized incidence ratio were calculated. RESULTS:
f 127 PTEN mutation carriers, 69 underwent 1 or more
ndoscopies with 64 (93%) having polyps. Of the 64, half
ad hyperplastic polyps. There were one to innumerable
olyps in the colorectum, ileum, duodenum, stomach,
nd/or esophagus, with 24 subjects having both upper
nd lower GI polyps. Nine (13%) subjects had colorectal
ancer, all younger than the age of 50. The adjusted
tandardized incidence ratio was 224.1 (95% confidence
nterval, 109.3– 411.3; P  .0001). CONCLUSIONS:
TEN-associated CS should be considered a mixed
olyp syndrome, with hyperplastic polyps most preva-
ent, with a risk of early onset colorectal cancer. Routine
olonoscopy should be considered in PTEN-associated
S, especially in the context of hyperplastic and/or ad-
nomatous polyps.
eywords: Colorectal Cancer; Cowden Syndrome; Hamar-
omatous Polyposis; PTEN.
owden syndrome (CS) often is considered a rare
hamartomatous polyposis syndrome caused by
ermline alterations in the tumor-suppressor gene phos-
hatase and tensin homolog (PTEN).1 It is thought to occur
n 1 in 200,000 individuals; however, experts believe thiss likely an underestimate because of the variable expres-
ion and subtle physical manifestations.2 CS is one of the
isorders that comprises the PTEN hamartoma tumor
yndrome.3 It is an autosomal-dominant disorder that is
haracterized by mucocutaneous lesions, macrocephaly,
nd an increased risk of benign and malignant diseases of
he breast, thyroid, and endometrium.2,3 Although the
astrointestinal (GI) tract is affected in individuals with
S, it has not been assessed systematically.
Published case reports and highly selected small series
eveal that 35%– 85% of CS patients had GI hamartoma-
ous polyps.4 –9 Although a majority of patients have been
escribed to have hamartomatous polyps, they also have
een reported to have ganglioneuromatous polyps, co-
onic lipomas and lymphoid aggregates, and hyperplastic,
denomatous, and inflammatory polyps. These polyps
ave been reported to occur in the esophagus, stomach,
uodenum, jejunum, ileum, colon and rectum, with the
olon being the site most often affected.
Whether GI neoplasias, especially malignancies, are
rue component phenotypes of CS is not known because
his association has not been studied systematically in a
arge series.10 Various case reports of colorectal cancer in
atients with CS have been published, mainly before the
id-2000s and often without the advantage of PTEN
utation status.5,11–13 In a series of 93 Japanese patients,
(9.6%) were reported to have colon cancer.14 Gastric
ancer has been highlighted in case reports of 2 individ-
als with CS.15,16 The risk of benign and malignant GI
eoplasias has not been characterized in a large series of
ndividuals with PTEN mutation–positive CS. We there-
ore sought to determine the prevalence and characteris-
ics of the GI phenotype in our series of PTEN mutation–
ositive subjects.
Abbreviations used in this paper: CS, Cowden syndrome; GI, gastro-
ntestinal; HPS, hyperplastic polyposis syndrome; ICC, International
owden Consortium; PTEN, phosphatase and tensin homolog; SIR,
tandardized incidence ratio.
© 2010 by the AGA Institute
0016-5085/$36.00doi:10.1053/j.gastro.2010.06.061
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1928 HEALD ET AL GASTROENTEROLOGY Vol. 139, No. 6Materials and Methods
Study Design
Between October 2005 and June 2009, subjects
ere prospectively recruited into a DNA banking proto-
ol approved by the Institutional Review Board for Hu-
an Subjects’ Protection of the Cleveland Clinic. Sub-
ects were selected from enrollees from 2 systematic
rospective cohorts: (1) those who met relaxed Interna-
ional Cowden Consortium (ICC) operational criteria (a
athognomonic mucocutaneous lesion, at least 1 major
riterion with or without minor criteria, or at least 2
inor criteria), or (2) those who had at least 5 gastroin-
estinal polyps, at least 1 of which must have been hy-
erplastic or hamartomatous (Figure 1). Enrollees into
hese 2 protocols originate from primary care clinics in
he community setting to genetics or oncology clinics in
cademic medical centers throughout North America
nd Europe. Upon providing informed consent, subjects
rovided a DNA sample and self-reported personal and
amily medical history. When available, medical records
ocumenting the subject’s history of neoplasias were
btained. All subjects underwent mutation analysis of
he PTEN gene, and only those found to have a dele-
erious germline mutation were included in the
resent study. Subject medical records were reviewed
or any endoscopy (esophagogastroduodenoscopy
nd/or colonoscopy) records and surgical pathology
eports documenting GI neoplasms (polyps, carci-
igure 1. Prospective accrual of individuals meeting relaxed ICC cri-
eria or the 5-polyp criteria and carrying clear pathogenic PTEN muta-
ions. To be conservative, individuals with variants of unknown signifi-
ance or promoter variants were excluded.oma), and those findings are reported descriptively. tPTEN Mutation Analysis
Genomic DNA was extracted from peripheral
lood leukocytes. Intragenic PTEN was analyzed with a
ombination of polymerase chain reaction– based dena-
uring gradient gel electrophoresis and direct sequencing
ABI 3730xl) as previously reported.17 PTEN promoter
utations and large deletions/rearrangements were as-
essed as previously described.18
Statistical Methods and Data Analysis
The Fisher 2-tailed exact test and unpaired t tests
ere used for comparison of PTEN mutation–positive
atients with and without polyps. An age- and sex-ad-
usted standardized incidence ratio (SIR) was calculated
o compare the incidence of colorectal and gastric cancers
n our series with that of the Surveillance Epidemiology
nd End Results database.
Results
Patients who met relaxed ICC criteria (N  2548)
r with 5 or more GI (any location) polyps, 1 or more of
hich was hyperplastic or hamartomatous (N  397),
ere prospectively recruited (Figure 1). Of the 2945 total
ubjects from these 2 prospectively accruing protocols
see Materials and Methods section for details), 127 pa-
ients with clear pathogenic PTEN mutations were eligi-
le for this study (Figure 1). Four of these subjects were
nrolled from the cohort ascertained by the presence of at
east 5 GI polyps, at least 1 of which was hyperplastic or
amartomatous, and the remaining 123 were enrolled
rom those who met relaxed ICC criteria (Figure 1). In
ur series of 127 PTEN mutation–positive individuals,
here were 8 individuals who might be clinically diag-
osed with Bannayan-Riley-Ruvalcaba syndrome, com-
rising 5 male individuals with penile freckling and mac-
ocephaly, 3 of whom also had lipomatosis. The
emaining 3 were females, all of whom had macroceph-
ly, at least 1 lipoma (not lipomatosis), and 1 vascular
nomaly. None of these 8 individuals had GI malignan-
ies. The average age at study enrollment was 34.6 years
range, 1–73 y), and 63 (49.6%) were male. A majority of
ubjects were white (78), of which 4 were Hispanic/
atino, with the remaining black or African American (9),
merican Indian or Alaska Native (8), or Asian (6). Race
as unknown for 26 subjects.
Of the 127 eligible subjects, GI polyps were reported in
4 (50.4%), with 24 having both upper- and lower-GI
olyps, 2 with only upper-GI polyps, and 38 with only
olorectal polyps. Subjects with polyps were significantly
lder (age, 42.0 y) at the time of enrollment compared
ith those without polyps (age, 26.6 y; P  .0001). No
ifferences in sex were observed between those with and
hose without polyps. There was no clear genotype–phe-
otype correlations for those with or without polyps or
hose with or without malignancies.
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December 2010 GI POLYPS AND CANCERS IN COWDEN SYNDROME 1929Colorectal Polyps and Carcinomas
At least one colonoscopy was performed for 67
52.8%) subjects. The average age at first colonoscopy was
6.4 years (range, 1–73 y). Twenty patients underwent
olonoscopy because they were symptomatic (abdominal
ain, bleeding, constipation, protein-losing enteropathy);
had the procedure because of the diagnosis of CS; 7
nderwent a general population screening colonoscopy; 7
ad the procedure because of a personal/family history of
olyps; and 2 had the procedure for other reasons (rec-
ovaginal fistula and history of cervical cancer). For 23
ubjects, the reason for the procedure was unknown.
nly 4 patients had a normal GI examination. Colorectal
olyps were identified in 62 subjects (representing 95% of
hose who underwent 1 colonoscopy, or 49% of all
ligible subjects) and 9 (representing 13% of all who
nderwent 1 colonoscopy, or 7.1% of all eligible sub-
ects) had adenocarcinomas, 1 had rectal cancer, and the
emaining 8 had colon cancers (Table 1).
The lower-GI polyps were found throughout the colon
nd rectum (Table 1). Of the 62 subjects with colorectal
olyps, 18 were found to have hamartomatous polyps, 27
yperplastic, 16 ganglioneuromatous, 16 adenomatous,
nd 11 inflammatory (Table 1). At least 9 subjects had
olyps of 3 different histologic types. Of the 27 subjects
ith colorectal hyperplastic polyps, at least 16 met the
perational diagnosis of hyperplastic polyposis syndrome
HPS).
The 9 colorectal cancers were diagnosed in 5 females
nd 4 males (Table 1). The average age at diagnosis was
4.4 years (range, 35– 49 y). Notably, the age- and sex-
djusted SIR for colorectal cancer in our series was 224.1
95% CI, 109.3– 411.3; P  .0001). One patient, subject
466, presented with colorectal adenocarcinoma in the
bsence of polyps, and never went on to develop pol-
ps. Three individuals with adenocarcinomas were
ound to have synchronous adenomatous polyps. In
ther words, of the 16 individuals with adenomatous
olyps, 3 (18%) developed colorectal cancer. Two of
hese 3 individuals with adenomatous polyps and colo-
ectal cancers also had hyperplastic polyps. Five indi-
iduals with colorectal carcinomas each had multiple
nonadenomatous) polyps, chief of which were hyper-
lastic (Table 1). Said another way, of the 27 subjects
ith hyperplastic polyps, 4 (15%) had colorectal carci-
omas. Three of these 4 individuals met the clinical
iagnosis of hyperplastic polyposis as well.
Upper-GI Findings
Thirty-nine (30.7%) subjects underwent at least
ne esophagogastroduodenoscopy. The average age at
rst esophagogastroduodenoscopy was 39.7 years (range,
–73 y). The most common indication for undergoing
sophagogastroduodenoscopy were symptoms including
eight loss (N  1), abdominal pain (3), esophagitis (1),
astroesophageal reflux disease (2), vomiting (1), dyspha- ria (4), diarrhea (2), hematochezia (1), anemia (1), and GI
ymptoms that were not otherwise specified (1). Five
ubjects had the examination because of the diagnosis of
S, 6 because of a history of colonic polyps, 9 for un-
nown reasons, and 2 for other reasons (history of ulcer-
tive colitis and an abnormal computed tomography
can). Of the 39 subjects, only 1 subject had a normal
xamination. Gastritis or inflammation was present in 7
17.9%) subjects and 8 (20.5%) had glycogenic acanthosis
Table 2). Upper-GI polyps were found in 26 (66.7%)
ubjects within the esophagus, stomach, and duodenum
Table 2). Only 2 individuals had fundic gland polyps. In
ddition, subject 985, who was white, was diagnosed in
is late 60s with invasive moderately to poorly differen-
iated adenocarcinoma with signet ring features arising
n a large hyperplastic/hamartomatous gastric polyp. Al-
hough only a single individual, age- and sex-adjusted
IR for gastric cancer in this series is 148 (range, 7.4 –733;
 .001). This individual also had diffuse hyperplastic
olyposis of the upper (and lower) tracts.
CS Clinical Features
Clinical features characteristic of or suspicious of
S also were recorded for all 127 subjects (Table 3). As a
ontrol, we note that breast cancer occurred in approxi-
ately 37% (age- and sex-adjusted SIR, 22; P  .001)
nd thyroid cancer in 16.5% (adjusted SIR, 65; P 
001) of these PTEN mutation carriers, within the ranges
f previous estimates and the single population-based
linical epidemiologic study by Starink et al.3,19 Macro-
ephaly was found in the great majority and was the
ost common clinical feature in our series of PTEN
utation carriers (95 subjects [74.8%]). Somewhat sur-
risingly, GI polyps occurred in 50.4% of all eligible
ubjects or 93% of eligible subjects undergoing at least
ne colonoscopy, making them the second most com-
on phenotypic feature only after macrocephaly.
Discussion
Recognition of pertinent personal medical and
amily history features as well as physical manifestations
s critical for accurate diagnosis, risk assessment, genetic
esting, and medical management for individuals with
ereditary cancer syndromes. Textbooks and single case
eports have noted the association of CS and hamar-
omatous polyps for some time, but not necessarily based
n systematic analysis. However, it remains an under-
cknowledged manifestation of the disorder for several
easons, perhaps because the malignant potential of
hese polyps is not well characterized and because there
as yet to be a systematic series addressing even the
requency and characteristics of the polyp histology. In
ur series of all patients with germline pathogenic PTEN
utations, GI polyps occurred in 50.4%, making it the
econd most common CS feature. Considering that colo-
ectal polyps occurred in 93% of our eligible subjects with
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1930 HEALD ET AL GASTROENTEROLOGY Vol. 139, No. 6ermline PTEN mutations who underwent at least one
olonoscopy, and approximately half of the entire series,
his 50.4% prevalence of any GI polyp is likely an under-
stimate. Notably, in addition to the textbook-acknowl-
able 1. Colorectal Polyps, Their Histology, and Colorectal Ad
Subject PTEN mutation Hamartom Hyperplastic G
1306-3 IVS62TC 1
3159 R335X 1
2834 Q17X 10
1515 P95L 50
68 302delT Multiple
651-2 461delT Multiple
3349 512insA Multiple
86 470insG Numerous
451 R335X Multiple
547 PTEN/BMPR1A
deletion
Multiple
2782 26delT Multiple
521-2 R130X Multiple
178 R130X 1 2
3015 734del4 2
2381 C211X Multiple Multiple
1824-1 Exon 2 deletion Multiple Multiple
3028 10q23.2-10q23.31
deletion
Numerous N
385 592_601del10 Numerous Numerous N
3007 R159T 1
393 M35V 4
2447 C136R 9
2736 R173C Multiple
1879 R355X 2 C
2224 R335X 2
958 Exon 1 deletion 5
1140 G132D 3
1083 19insCT 2
2438 L345V 3
1968 2091GT Multiple M
3605 210-2_211delAGTT Multiple M
417 350insA 3
907 895insTA Multiple
2127 Y240X Carpet
237-2 C136Y Numerous
3577 L181P Multiple
1824-2 Exon 2 del Multiple
723 542delT Multiple
985 1019delA Multiple
111 R130X Innumerable
294 1027-2AC Multiple
37 C211X Multiple
1694 10261GC
3935 R130X
622 C136R M
2370 491delA M
139 2531GA N
2544 407del17 N
2539 968delA N
1094 635-1GC N
47 R130X M
559 R130Q
2986 R233X
1027 A120E
1306-1 IVS62TC
77 S229X
2466 H61R
1334-2 210-1GA
1495 R335X
1334 210-1GA
180 P96R
4-3 G219X
367 870delA
2613 406insA
OTE. Quantitation of polyps derives from endoscopy reports. Subject 37 has
amartom, hamartomatous polyps; Hyperplastic, hyperplastic polyps; Ganglion
atory polyps; LA, lymphoid aggregates; path, pathology; SSP, sessile serratedged hamartomatous polyps, we show here that oyperplastic polyps, ganglioneuromatous polyps, and ad-
nomatous polyps are important components of the CS
olyp histology. In fact, at least half of our mutation
arriers who were shown to have colorectal polyps had 2
carcinomas in PTEN Mutation Carriers
neur Adenoma Inflamm Other
Lipomas
us Numerous
us Numerous LA
ng
2
2
2 1 2 SSP
6 Lipomas
LA
Multiple LA
Multiple Adenocarcinoma
Pan-colonic Adenocarcinoma
1
2 Adenocarcinoma
Numerous
Multiple Multiple
Multiple Multiple
Multiple Multiple
Multiple
Lipomas
Adenocarcinoma
Adenocarcinoma
0 Adenocarcinoma
us
us
us 4
us Numerous
Multiple Adenocarcinoma
1
13 Adenocarcinoma
Multiple Multiple
30-40 SSP; LA
Polypoid mucosa
Adenocarcinoma
1 polyp, unknown path
2 polyps, unknown path
50–100 polyps, unknown path
Many polyps, unknown path
Polyps, unknown path or number
Polyps, unknown path or number
Polyps, unknown path or number
reported previously in the literature.13
ganglioneuromatous polyps; Adenoma, adenomatous polyps; Inflamm, inflam-
ps.eno
anglio
1
3
umero
umero
arpeti
ultiple
ultiple
3
4
ultiple
ultiple
umero
umero
umero
umero
ultiple
beenr more histologic types.
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December 2010 GI POLYPS AND CANCERS IN COWDEN SYNDROME 1931In an effort to create uniform criteria in 1995 for the
urposes of identifying the predisposition gene, the ICC
eveloped consensus operational diagnostic criteria,20,21
hich were revised in 2000, in an attempt to broaden the
et for clinical use.2 These criteria specify that GI hamar-
omas are a minor criterion because of a lack of system-
tic study. If the ICC criteria were amended to include GI
olyps as a major criterion, then an additional 21 (16.5%)
ubjects would have had a clinical diagnosis of CS at the
ime of study enrollment. The most recent version of the
ational Comprehensive Cancer Network CS testing cri-
eria was updated to include multiple GI hamartomas or
anglioneuromas as a major criterion and a single GI
amartoma or ganglioneuroma as a minor criterion
ased on expert opinion in the context of single case
eports and highly selected small series, often without
TEN mutation information.22 The observations from
able 2. The Number of Polyps and Corresponding Pathology
Carriers
Subject PTEN mutation Hamartom Hy
68 302delT 15
1306-1 IVS62TC Multiple
3349 512insA Multiple
521-2 R130X Multiple
3028 10q23.2-10q23.31 deletion Few
912 R130X Several
393 M35V 3
417 350insA Mu
165 48insA Inn
1027 A120E My
1140 G132D Mu
2782 26delT Mu
985 1019delA Di
1083 19insCT Mu
2370 491delA
178 R130X
1879 R355X
294 1027-2AC
723 542delT
47 R130X
86 470insG
180 P96R
2381 C211X
2986 R233X
2834 Q17X
37 C211X
OTE. Quantitation of polyps derives from endoscopy reports.
amartom, hamartomatous polyps; Hyperplastic, hyperplastic polyps;
GP, fundic gland polyps; path, pathology.ur prospective systematic study lend objective support co the changes to the National Comprehensive Cancer
etwork testing criteria.
For patients who are suspicious for the PTEN hamar-
oma tumor syndrome, it is important to assess previous
istory of GI polyps. Efforts should be made to confirm
he polyp burden in these patients with medical records.
n addition, given the inaccuracies with polyp histolo-
y,23 consideration should be given to having the pathol-
gy re-reviewed by a dedicated GI pathologist. For pa-
ients suspicious for CS or a PTEN hamartoma tumor
yndrome who have not previously undergone an endos-
opy, the risks and benefits of a baseline upper endoscopy
nd colonoscopy should be considered in the diagnostic
ork-up.
Colorectal cancer occurred in 7.1% of our entire series
nd 13% of eligible subjects who underwent at least one
olonoscopy (age- and sex-adjusted SIR, 224). Currently,
he Upper-GI Polyps Found in PTEN Mutation–Positive
astic Ganglioneur Adenoma Other
1
2 Polypoid mucosa
Multiple
rable
Few FGP
Multiple
inflammatory
polyps
Adenocarcinoma;
FGP
Multiple
inflammatory
polyps
Multiple
Polypoid mucosa
Polypoid mucosa
Polypoid mucosa
Polypoid mucosa
Polypoid mucosa
Polypoid mucosa
Many polyps,
unknown path
Many polyps,
unknown path
Multiple polyps,
unknown path
Multiple polyps,
unknown path
Hundreds of polyps,
unknown path
lioneur, ganglioneuromatous polyps; Adenoma, adenomatous polyps;of t
perpl
ltiple
ume
riads
ltiple
ltiple
ffuse
ltiple
Gangolorectal surveillance is not routinely recommended for
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1932 HEALD ET AL GASTROENTEROLOGY Vol. 139, No. 6ndividuals with CS beyond that for the general popula-
ion. However, in our series, all 9 subjects were diagnosed
ith colorectal cancer before age 50, with the youngest
ge at diagnosis being 35 years. Therefore, had our sub-
ects initiated screening at age 50, their malignancies
ould likely not have been detected until an advanced
tage. Individuals with PTEN mutations may benefit
rom earlier colonic surveillance. One group has advised
“vigorous” screening approach for patients with CS
hat includes colonoscopy beginning at age 15 with fol-
ow-up evaluation every 1–2 years.24 This approach is
ather aggressive. Based on our current observations, we
ecommend considering a baseline colonoscopy at age 35,
r sooner if symptoms develop, with follow-up time
ased on polyp burden.
Based on our series, approximately 15% of PTEN mu-
ation carriers with colorectal hyperplastic polyps devel-
ped colorectal cancer, and almost 20% of mutation
arriers with colorectal adenomas had colorectal cancer.
he patients who developed colorectal carcinomas also
ended to have multiple polyps, based on small numbers.
herefore, if these observations can be reconfirmed in an
ndependent series, then colorectal surveillance should be
ffered to any PTEN mutation carrier with multiple low-
r-GI polyps, and/or the presence of hyperplastic and/or
denomatous polyps.
There were 2 (13%) individuals with sessile serrated
denomas, both of whom were among the 16 individuals
ho met the criteria for hyperplastic polyposis syndrome.
here are 2 interpretations to this observation: that this
s a true representation, or there was uneven diagnosis of
his histology among the pathologists. We tried to gauge
his by culling out our research subjects enrolled in
able 3. Frequency of CS Features Observed in our PTEN
Mutation–Positive Series
CS feature Frequency (%)
acrocephaly 95 (74.8)
I polyps 64 (50.4)
oiter/thyroid nodules 56 (44.1)
enign breast diseasea 24 (37.5)
reast cancera 24 (37.5)
ipomas 44 (34.6)
apillomatous papules 43 (33.9)
ndometrial fibroidsa 17 (26.6)
richilemmomas 26 (20.5)
enile frecklingb 12 (19.0)
cral keratoses 21 (16.5)
ental retardation/developmental delay 21 (16.5)
hyroid cancer 21 (16.5)
ndometrial cancera 8 (12.5)
olorectal cancer 9 (7.1)
hermitte–Duclos disease 8 (6.3)
utism 8 (6.3)
OTE. GI polyps are the second most common feature.
Female subjects only.
Male subjects only.nother study (who may or may not have PTEN muta- mions) during a similar period, and we found that of those
ho met the diagnosis of HPS, approximately 50% also
ad sessile serrated adenomas (P  .07).
Only one individual in our series developed gastric
ancer. Although the formal adjusted SIR is increased, we
annot draw genetic counseling or clinical conclusions
iven that this single subject was a white male who
eveloped gastric cancer at age 67. It is nonetheless in-
eresting to note the co-existing diffuse hyperplastic pol-
posis in the stomach and duodenum, almost mirroring
he situation in the colon. In our series of PTEN muta-
ions carriers, upper-GI polyps do occur with some fre-
uency, and, for a subset of patients, they do experience
ymptoms. Excluding the 5 individuals with unknown
olyp histology in the upper-GI tract, 15 of the 19 with
olyps in the upper and lower tracts had concordant
istologies. Interestingly, fundic gland polyps, often said
o be indicative of CS, were found in only 2 mutation
arriers. Notably, 20% of those with GI examinations had
lycogenic acanthosis. Although no consensus guidelines
xist regarding upper-GI management in CS, Schreibman
t al24 recommend upper endoscopy and an upper-GI
eries with small-bowel follow-through beginning at age
5 with follow-up evaluation every 2 years. Again, based
n our current observations, we believe that this ap-
roach is rather aggressive and recommend upper-GI
urveillance only for symptom management, at least in
he white population. Based on anecdotal reports on
sian populations, we suspect that GI features, perhaps
ven upper-GI malignancies, may be more prominent in
he Asian population.
One of the major limitations of this study was that not
ll medical records were available to confirm all of the
eported histories, although these remain in the minor-
ty. Therefore, we do not have detailed information about
he precise GI history for some patients. Further, because
atients were recruited from multiple medical centers,
here is wide variability in the medical reports and pa-
hology expertise available. The most ideal study would
e to offer at least baseline colonoscopy, by a limited
umber of endoscopists, and to have the pathology re-
iewed by a single pathologist with expertise in hereditary
I disease to accurately capture the frequency with which
I polyps occur in these patients. Nonetheless, despite
hese limitations, the conditions of the study do some-
hat simulate the data available at a high-risk GI con-
ultation.
Based on the observations from our prospectively ac-
rued series of PTEN mutation carriers and the literature,
e conclude that both upper- and lower-GI polyps are
ommon component features of the PTEN hamartoma
umor syndrome. The presence of nonadenomatous pol-
ps, and especially comprising mixed histologies, should
ignal a health care provider to refer such individuals for
igh-risk assessment. Furthermore, the presence of both
acrocephaly and nonadenomatous GI polyps together
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ermline PTEN mutations. Colorectal adenomas usually
re not considered part of the CS phenotype, but our
eries suggests that they most likely are, with almost 20%
f PTEN mutation carriers with colorectal adenomatous
olyps developing colorectal adenocarcinomas. Similarly,
ultiple colorectal polyps of any histology and hyper-
lastic polyps, especially a hyperplastic polyposis syn-
rome phenotype, may be red flags for PTEN mutation
arriers developing colorectal cancers. Importantly, colo-
ectal adenocarcinomas have an increased prevalence in
TEN mutation carriers, all occurring before the age of
0 years, and therefore routine colonic surveillance
hould be considered.
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